US EditionOcugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
CHESTER COUNTY, PENNSYLVANIA, AUG 8 – Ocugen raised $20 million through a registered direct offering with Janus Henderson Investors to fund gene therapies targeting blindness, selling 20 million shares and warrants.
3 Articles
3 Articles
Hastings Tribune
ADKhabarOcugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it has entered into a securities purchase agreement with Janus Henderson…
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants - Ocugen (NASDAQ:OCGN)
MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it has entered into a securities purchase agreement with Janus Henderson Investors, a global asset management firm, to purchase 20,000,000 shares of common stock and warrants to purchase up to an aggregate of 20,000,000 shares of common stock at a purc…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
